CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 18 enrolled
Drug / intervention
Xanax 1Mg Tablet +2 moredrug
Likely dose
Xanax 1Mg Tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03447353
NCT03447353Phase 4Completed
CompareCT.gov

SAFER-SIM: Opiates and Benzodiazepines on Driving

Timothy L. Brown·interventional·Posted Feb 27, 2018·Updated Sep 27, 2018

In Brief

A Phase 4 clinical trial evaluating Xanax 1Mg Tablet, Norco 10Mg-325Mg Tablet, and 1 other intervention for Driving Behavior. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The aim of this research is to assess drug effects (Xanax and Norco) on driving performance. Researchers will use the Alertness Memory Profiler (AMP) application to compare results to previous related studies. This study continues a line of research designed to characterize the effects of common recreationally used prescription and illicit drugs with well known stimulant and sedating effects and their relationship to results from the Alertness Memory Profiler (AMP) that included a set of vigilance and memory tasks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDriving Behavior
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 27, 2018
Enrollment StartJun 14, 2016
Primary CompletionOct 25, 2016
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 8.3 years ago

Interventions

Xanax 1Mg Tabletdrug

Single dose on two of four visits, one in conjunction with 1 tab of 10mg/325mg Norco

Norco 10Mg-325Mg Tabletdrug

Single dose on two of the four study visits, one in conjunction with 1mg alprazolam

Placebo Oral Tabletdrug

Single dose on two of the four study visits, double dose on one of the four study visits